New Endpoints for Chronic Kidney Disease?


How do we decide if a therapy slows the progression of chronic kidney disease? In the past, doubling of serum creatinine has been accepted by the Food and Drug Administration (FDA). Recent studies have used smaller changes in estimated glomerular filtration rate as endpoints, and the FDA has convened a group to formally address the issue. New endpoints could facilitate clinical trials of new treatments, getting drugs tested and on the market sooner.